GLP-1 drugs not linked to suicidal thoughts, early FDA review finds

As use of drugs like Ozempic and Zepbound rises, agencies have yet to find causal links between usage and reports of suicidal thoughts.

January 11, 2024 Check out STAT+

Sponsored By

Sarah Silbiger/Getty Images GLP-1 drugs not linked to suicidal thoughts in FDA's early review Its preliminary analysis found no link but the agency will continue to review anecdotal reports about blockbusters like Ozempic and Zepbound. By Elaine Chen STAT+ | Courts will decide the future of Medicare's power to negotiate drug prices within months Pharmaceutical companies' efforts to scuttle President Biden's program letting Medicare negotiate drug prices will soon face a big test. By Rachel Cohrs STAT+ | A biotech reporter's notebook: Sunshine rains down on San Francisco Whatever the reason, sentiment at this year's J.P. Morgan Healthcare Conference in San Francisco was markedly more positive than in recent years. By Allison DeAngelis Adobe Opinion: Pumping milk at JPM was a nightmare. It's part of a bigger problem in the industry JPM didn't take its accommodations for new mothers seriously — a failure that's all too common in the health care industry. By Tara Bannow Patients' social needs often get lost in health records. Generative AI could help Factors like housing, transportation, and income play a critical role in patients' health, and generative AI can identify those needs. By Katie Palmer Opinion: Addressing the Black youth suicide crisis requires a new approach to licensing clinical social workers There is an urgent need to provide affordable and accessible mental health treatment that reaches Black Americans. By Janelle Goodwill Listen: Live! From JPM 2024 At the JP Morgan Healthcare Conference, we discuss how there seems to be a brighter outlook for biotech at the outset of 2024. By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT+ | Rune Labs, which makes an app to track Parkinson's symptoms, raises $12 million Rune Labs announced it raised $12 million in funding led by Nexus NeuroTech, a new venture capital fund focused on brain disorders. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser